NICE disapproves the use of cancer drug Tarceva
13th Nov 2006, 21:58 GMT
A recent decision taken by the National Institute for Health and Clinical Excellence (NICE) disapproving the use of Tarceva (erlotinib), used for treating non-small cell lung cancer, has caused an uproar among the cancer specialists and thousands of lung cancer patients all over England.
NICE disapproves the use of cancer drug Tarceva related news:
- NICE rejects use of cancer drug Tarceva — Pharmaceutical Business Review Latest News
- NICE consults on advice on two treatments for NSCLC — OnMedica Latest News
- NICE refuse to fund life-prolonging cancer drug available in Scotland — the Mail online | Health
- NICE refuses to fund life-prolonging cancer drug available in Scotland — the Mail online | Health
- Watchdog rules against new treatment for lung cancer — Guardian Unlimited UK Latest
- NICE refuses to fund £20,000 cancer drug available in Scotland — the Mail online | Home
- Targeted cancer drugs may work by disrupting balance of cellular signals — EurekAlert! - Cancer
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
- Dendreon completes FDA filing for prostate-cancer drug — The Seattle Times: Horse racing
- Cancer drug guidance concern — BBC News | Health | UK Edition
Latest news from The Earth Times Online Newspaper:
- Does Zune sing a better tune?
- Lebanon approves international tribunal for Hariri killers
- Canadian oil company Centurion bought by UAE-based Dana Gas
- TroVax vaccine produces encouraging results in Phase II trials
- The battle of the gaming consoles
- BHP Billiton, allies buy Gulf of Mexico oil field Genghis Khan
- U.K. house price inflation up in September
- Seoul not to participate in ship interception plan
- Spiderman star Toby Maguire is a proud father
- Hamas ready for peace talks with Israel; Arab League promises aid to Palestinians